ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
äŒæ¥ã³ãŒãADMA
äŒç€ŸåADMA Biologics Inc
äžå Žæ¥Oct 17, 2013
æé«çµå¶è²¬ä»»è
ãCEOãGrossman (Adam S)
åŸæ¥å¡æ°677
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 17
æ¬ç€Ÿæåšå°465 State Route 17
éœåžRAMSEY
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·07446
é»è©±çªå·12014785552
ãŠã§ããµã€ãhttps://www.admabiologics.com/
äŒæ¥ã³ãŒãADMA
äžå Žæ¥Oct 17, 2013
æé«çµå¶è²¬ä»»è
ãCEOãGrossman (Adam S)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã